We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana and Interwell Health Expand Value-Based Support to Florida
Read MoreHide Full Article
Humana Inc. (HUM - Free Report) recently announced the expansion of its value-based care agreement to include eligible Medicare Advantage members in Florida. Humana and Interwell Health will provide value-based support services for eligible members suffering from chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The services are available in 14 and 39 states for members with CKD and ESKD, respectively.
This move bodes well for Humana as it will enhance the quality of care and improve health outcomes for patients suffering from chronic kidney diseases. In a recently released issue brief, HUM highlighted that value-based care partnerships, specifically for kidney care, reduced unessential hospital discharges by 5% in 2023.
This is a time opportune move as tens of millions of Americans suffer from chronic kidney disease. HUM aims to continually expand and enhance its patient-friendly kidney care programs. This move is expected to aid in improving the retention of Medicare Advantage clients. Interwell Health’s resources will be available for access, incorporating 2,000 network nephrologists and renal care coordinators, amongst others.
This move highlights HUM’s focus on value-based care models. Its value-based care models will help in managing chronic conditions effectively. This, along with better patient outcomes, poises HUM to reduce overall healthcare costs and lower benefits.
Humana derives a major portion of its revenues from Medicare Advantage premiums. Its Medicare Advantage membership improved in the second quarter, benefiting its results. However, the benefits expense ratio deteriorated 270 bps, highlighting an increase in medical cost trends. HUM expects Medicare Advantage membership to grow 225,000 in 2024.
Image Source: Zacks Investment Research
HUM’s Price Performance
Shares of Humana have lost 13.5% in the past three months against the industry’s 13.9% growth.
Tenet Healthcare’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 58.48%. The consensus estimate for THC’s 2024 earnings and revenues indicates an improvement of 53.6% and 1.4%, respectively, from the 2023 reported figures. The consensus estimate for Tenet Healthcare’s earnings has moved 5.6% north in the past 60 days.
HCA Healthcare’s earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 8.24%. The consensus estimate for HCA’s 2024 earnings and revenues implies an improvement of 18.2% and 8.9% from the respective 2023 figures. The consensus estimate for HCA Healthcare’s 2024 earnings has moved 1.2% north in the past 30 days.
Integer Holdings’ earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 7.83%. The consensus estimate for ITGR’s 2024 earnings and revenues indicates an improvement of 13.7% and 9.6%, respectively, from the 2023 figures. The consensus estimate for Integer Holdings’ 2024 earnings has moved 0.2% north in the past 60 days.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Humana and Interwell Health Expand Value-Based Support to Florida
Humana Inc. (HUM - Free Report) recently announced the expansion of its value-based care agreement to include eligible Medicare Advantage members in Florida. Humana and Interwell Health will provide value-based support services for eligible members suffering from chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The services are available in 14 and 39 states for members with CKD and ESKD, respectively.
This move bodes well for Humana as it will enhance the quality of care and improve health outcomes for patients suffering from chronic kidney diseases. In a recently released issue brief, HUM highlighted that value-based care partnerships, specifically for kidney care, reduced unessential hospital discharges by 5% in 2023.
This is a time opportune move as tens of millions of Americans suffer from chronic kidney disease. HUM aims to continually expand and enhance its patient-friendly kidney care programs. This move is expected to aid in improving the retention of Medicare Advantage clients. Interwell Health’s resources will be available for access, incorporating 2,000 network nephrologists and renal care coordinators, amongst others.
This move highlights HUM’s focus on value-based care models. Its value-based care models will help in managing chronic conditions effectively. This, along with better patient outcomes, poises HUM to reduce overall healthcare costs and lower benefits.
Humana derives a major portion of its revenues from Medicare Advantage premiums. Its Medicare Advantage membership improved in the second quarter, benefiting its results. However, the benefits expense ratio deteriorated 270 bps, highlighting an increase in medical cost trends. HUM expects Medicare Advantage membership to grow 225,000 in 2024.
Image Source: Zacks Investment Research
HUM’s Price Performance
Shares of Humana have lost 13.5% in the past three months against the industry’s 13.9% growth.
Humana’s Zacks Rank and Stocks to Consider
HUM currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the Medical space are Tenet Healthcare Corporation (THC - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) and Integer Holdings Corporation (ITGR - Free Report) . While Tenet Healthcare sports a Zacks Rank #1 (Strong Buy) at present, HCA Healthcare and Integer Holdings carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Tenet Healthcare’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 58.48%. The consensus estimate for THC’s 2024 earnings and revenues indicates an improvement of 53.6% and 1.4%, respectively, from the 2023 reported figures. The consensus estimate for Tenet Healthcare’s earnings has moved 5.6% north in the past 60 days.
HCA Healthcare’s earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed the mark once, the average surprise being 8.24%. The consensus estimate for HCA’s 2024 earnings and revenues implies an improvement of 18.2% and 8.9% from the respective 2023 figures. The consensus estimate for HCA Healthcare’s 2024 earnings has moved 1.2% north in the past 30 days.
Integer Holdings’ earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 7.83%. The consensus estimate for ITGR’s 2024 earnings and revenues indicates an improvement of 13.7% and 9.6%, respectively, from the 2023 figures. The consensus estimate for Integer Holdings’ 2024 earnings has moved 0.2% north in the past 60 days.